Pharmacological studies have shown that DCHD can reduce vitreous degeneration, inhibit the production of glutamic-pyruvic transaminase (GPT), thus enhancing the activity of tryptophan oxygenase and glutamine synthetase, can inhibit carbon tetracloride, thus slowing down the development of cirrhosis, to achieve the purpose of protecting the liver (64). This evidence concerns the gene TDO2 and vitreous syneresis.